The neuroprotective agent loberamisal improved functional outcomes after acute ischemic stroke. The phase III study was placebo-controlled. Loberamisal thereby increased its prospects as an investigational neuroprotective therapy. The participants were patients with relatively minor symptoms. The study was conducted in New Orleans and the results were reported on MedPage Today.